It is now known that chemicals and drugs may induce selective toxicity which may alter the interactions between immunocompetent cells, especially if the toxicity occurs during proliferation and differentiation.
INTRODUCTION
The immune system is a highly regulated network of lymphoid cells that requires continued renewal, activation, and differentiation for full immunological competence. The functions of the immune system include discrimination of self from non-self and defense against infectious micro-organisms and spontaneously arising neoplasia. Cell depletion, dysregulation, and functional deficits within this cellular network can result in a pathological process marked by altered responses to self-and nonselfantigens or increased susceptibility to infectious agents and tumor cells. It can therefore be easily appreciated that the immune system may be a fre- quent target organ for cytotoxic drug and non-drug chemicals. A large number of diverse compounds or their metabolites possesses the capacity to induce autoimmunity or allergic responses in susceptible individuals (e.g., diisocyanates, penicillamine) (Table I). Conversely, immunosuppression has been well-documented to occur following exposure of humans or animals to a wide range of chemicals (Table  11) , including inorganic pollutants, halogenated and non-halogenated aromatic hydrocarbons, and therapeutic agents. Although several chemicals of occupational or environmental concern have produced immune modification in rodents and are suspected of producing similar effects in humans, in most cases rigorous clinical confirmation of altered immunological responsiveness is incomplete. Immunomodulatory activity (i.e., immunosuppression or immune enhancement) has been beneficially exploited in thc development of anti-neoplastic 265 TOXICOLOGIC PATHOLOGY agents and so-called biological response modifiers (BRMs) proposed for immunotherapy of immune deficiency and certain types of neoplasia. The distribution of mononuclear phagocytes and lymphocytes throughout the body requires that they cope with the many xenobiotics (e.g., physical agents, chemicals, and drugs) which enter via the skin, blood, digestive tract or pulmonary system. During the past decade, numerous studies have shown that exposure of rodents to chemicals or drugs by dosing protocols that did not cause overt toxicity often produced immune alterations sufficient .to result in altered host resistance to challenge with infectious agents or neoplastic cells (6,9,11 , 29) . For certain environmental agents, the relevance of many.of these rodent exposure studies to human health effects awaits further investigation. In the case of drugs such as cyclophosphamide, methotrexate, or cyclosporin A, the immune effects seen in rodents were comparable to immune alterations observed in the clinic (10) .
. Intentional or accidental exposure of humans to certain of these immunotoxic xenobiotics has pro- duced immunomodulation and an increased incidence of infectious disease or neoplasia (1 6,23). At least four incidences of accidental exposure have been reported to result in immunologic abnormalities: 1) Michigan farm residents exposed to polybrominated biphenyls contaminating dairy products and meat showed impaired lymphocyte blastogenesis to mitogens and E rosette formation (1 , 2); 2) an increased frequency of infectious disease followed exposure of Taiwanese and Japanese to rice oil contaminated with polychlorinated biphenyl (4, 3 1); 3) pneumonitis and Sjogren-like syndrome resulted from the ingestion of isothiocyanate-derived imidazolidinethione compounds in adulterated rapeseed oil sold as olive oil in Spain (3, 13, 16, 17) ; and 4) altered skin test reactivity to recall antigens and lymphocyte subset numbers occurred among Missouri residents exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (1 5). An increased incidence of pulmonary infections has also been observed in humans following exposure to noxious gases (e.g., ozone, nitrogen dioxide, sulfur dioxide) and airborne particulates (1 2, 18, 24, 25) . Although clinical studies of these accidental exposures have provided some data regarding human health effects, they do not define mechanisms of toxicity or clarify doseresponse relationships. Rodent models continue to provide the only means for such determinations and are crucial to the safety evaluation of chemicals.
Standardized protocols using animal models for immunotoxicological investigations may permit prediction of potential human toxicity. Such pro- tocols must be calibrated by assessing effects on human cells either in culture or following accidental exposure for comparison against the in vifro or in vivo results of animal studies.
COMPARATIVE TOXICOLOGY AND SAFETY ASSESSMENT Among the issues of comparative toxicology are the selection of appropriate animal models and the design of experimental protocols which accurately correspond to xenobiotic or metabolite exposure in the species of predominant interest, most frequently humans for risk assessment. It is crucial to weigh species variations in the design of toxicological studies for application to humans, since biological diversity may confound efforts for accurate predictions of toxicity. A well-designed toxicological study (e.g., the preclinical toxicology of cyclosporin A) provides reassurance that at least basic similarities exist in the toxicity between rodents and humans, and that these similarities also extend to the immunotoxicology and immunopharmacology of immunologically active agents (26, 28) . During the premarket development of a drug or chemical, the compound is screened to determine its toxicity profile in one or more rodent species. Table I11 summarizes the comparative immunosuppressive profile for the immunosuppressive drug cyclosporin A (CSA) in several species. The immunological effects produced and doses producing these endpoints were similar in all species. The rat was slightly more susceptible to the immunosuppressive effects of CSA than the mouse (2-10-fold higher dose required). This slight species difference was further reflected in the LD,, to CSA in these two rodent species (mouse: 2,329 mg/kg oral, rat: 1,480 mg/kg oral).
Despite the close correlation of toxicity profiles among species examined with cyclosporin A, toxic responses to a chemical are potentially variable among different species. Ideally, toxicity testing should be performed with a species that will elicit chemical-related pharmacology and toxicities similar to those anticipated in humans (i.e., the test animal and humans will metabolize the chemical similarly and will have identical target organ responses and toxicity). Toxicological studies are conducted in a variety of animal species since the ideal animal for extrapolation may not exist. Priority should be given to animal species that demonstrate metabolism, pharmacokinetics, pharmacological effects, and suspected target organ specificity as similar to humans as possible.
To further explore the issue of comparative toxicities among rodents, the toxicological profile, LD,, values, maximum tolerated dose (MTD), and therapeutic dose (humans only) were compared for CSA and two other widely used immunosuppressive drugs (Table IV) . The toxicity profile of CSA was essentially identical for all species examined. The therapeutic index (defined as ED,,,/LDSo, a relative measure of efficacy to toxicity) for this drug in humans is approximately 10-100. The toxicology profile of cyclophosphamide was similar in all species, although only primates exhibited cardiac toxicity as later seen in humans. There were only minor differences in LD,, and MTD values among the rodent and primate species to cyclophosphamide. Similarly, the folic acid antagonist methotrexate exhibits a comparable toxicological profile among humans and different rodent species. Rats were slightly more sensitive (5-fold) to the toxicity of methotrexate than were mice.
Rodent data on target organ toxicities and comparability of immunosuppressive doses has generally been predictive of what was later to be observed in the clinic with most immunosuppressive drugs. Exceptions to the predictive value of rodent toxicological data are infrequently seen, but have OCcurred in studies of glucocorticoids, which are lympholytic in rodents, but not in primates (14) . Although certain compounds may exhibit different pharmacokinetics (absorption, disposition, metabolism, and pharmacological effect) in rodents than in humans, rodents still appear to be the most appropriate animal model for examining the immunotoxicity of non-species-specific compounds, based on established similarities of toxicological profiles as well as the ease of generating host susceptibility challenge and immune function data. Comparative toxicological studies must be continued and expanded as novel recombinant biological compounds enter safety testing, since host interactions and species-specificity may present new toxicological profiles for consideration.
IMMUNOTOXICOLOGICAL ASSJXSMENT

IN RODENTS
The potential of the immune system as a target organ for xenobiotic toxicity stems from three characteristics of the system. First, functional immunocompetent cells are required for host resistance to infectious agents and neoplastic cells. Second, immunocompetent cells must undergo continual renewal via proliferation and differentiation to remain functional, and both processes are known to be quite sensitive to chemical perturbation. Third, a regulatory network of soluble factors and cell-cell contact is necessary for immunocompetence. Detrimental alterations in the balance of the immune regulatory network affecting critical interactions between lymphoid cells may cause detectable changes in discrete components of immune function. However, such alterations may still be within the "functional or physiological reserve" of the immune system and not produce significant impairment in the whole animal.
Immunotoxicity assessments require validation of the endpoints to be measured (quality control and biological relevance) as well as knowledgeable selection of animal models, exposure parameters, and other general toxicological parameters. The evaluation of functional immune capacity in rodents in- volves testing of specific immunologic functions in vitro and measurement of host resistance to disease. Correlations between in vitro functional tests and host resistance in rodents have been demonstrated (8). These may be combined with toxicological data to provide the most efficiently generated comparative data base for human risk estimation. Immune dysfunction produced by chemical or drug exposure is dependent upon the type of immunologic injury characteristic of the xenobiotic, the chemical threshold and toxicokinetics of the compound, and the functional reserve of the immune function affected. Dose selection is critical for the validity of immunologic assessment, since severe stress and malnutrition are known to impair immune responsiveness. The general toxicologic data base (including LD,,, LD,,, and MTD data) should be used when available to establish preliminary exposure protocols. Three exposure levels are recommended to establish dose-effect relationships; the lowest dose should cause no alteration in immune function. The highest dose used should be considerably lower than the LD,, and have no associated mortality (especially important in the design of host resistance studies). Selection of exposure route should parallel the probable natural route of exposure in humans, which is frequently oral (camed out by feeding dosed lab animal chow or water, or by gavage). A requirement for an accurate delivered dose may require the use of parenteral, subcutaneous, or intraperitoneal exposure routes. Because xenobiotic exposure of humans frequently occurs via the respiratory tract, a reasonable exposure pro-tocol for laboratory animals would be by inhalation or intratracheal instillation. All in vitro assays described herein are performed ex vivo following in vivo exposure of the animal to the test compound.
Two hallmarks of the complexity of the immune system are the diversity of immunomodulatory mechanisms and the variety of adverse effects that may be induced by immunotoxicants or immunomodulatory drugs. Therefore, preclinical or pre-release testing of xenobiotics suspected of immunotoxicity represents a process of extreme importance. A flexible, tiered approach to the safety assessment of potential immunotoxic chemicals or immunomodulatory drugs has been recommended as a logical and efficient testing protocol (21) . It was concluded that the immunologic evaluation encompassing a battery of validated and refined methods must maintain a suitable degree of flexibility because of the varied nature and characteristics of xenobiotic-induced alterations of the immune system. Assessment tiers would be expected to improve in sensitivity, predictive value, and cost effectiveness as they are applied. Most of the methods previously proposed (5,29) have recently undergone scientific validation through a limited interlaboratory comparison in the USA and have been extensively utilized in several laboratories (8, 20, 30) . A preliminary correlation has been demonstrated between depression of certain immune functions and increased susceptibility to challenge with certain defined infectious agents and transplantable tumor cells (8). Recently, a preclinical rodent screen was proposed for determining the appropriate dosing schedule and underlying mechanisms of action of biological response-modifying drugs or biologicals that have been newly proposed as therapeutic modalities (27), and for assessing their efficacy.
The structure of an immune function assay tier may vary somewhat among the various groups working in immunotoxicology and immunopharmacology, partly because of the use of different animal species. This is particularly true regarding the application of bacterial, viral, and tumor challenge models. A flexible approach for immunotoxicity assessment (22) was adapted by the National Toxicology Program (NTP) as part of its Special Studies Panel for Immunotoxicity Assessment and has undergone extensive validation (20) . The phase 1 panel currently used for immunotoxicity evaluation at the Chemical Industry Institute of Toxicology (CIIT) and in the NTP is divided into two levels (shown in Table V ) and encompasses both in vivo and in vitro measures of quantitative and functional changes in immune status. Level 1 testing can be performed in.the mouse or the rat as well as several other species. Detailed information on these methods (19) and the effects of chemicals on immune function in rodents can be obtained from several reviews (6, 9, 29) .
Although rodents are traditionally used for toxicity studies, precedent exists in toxicology for the selection of alternative species for special studies, e.g., drug evaluation in dogs, teratology studies in rabbits, and hypersensitivity testing in guinea pigs.
Inbred mice (notably the F1 hybrid mouse B6C3F1, which was derived from C57BU6 and C3H strains) are routinely used in the NTP to assess immune function, primarily because of the comparability of organ weights, pathology, and immune responsiveness among inbred strains. Rodent immune function data must be cautiously interpreted when proposing that functional changes associated with altered host resistance are of potential concern in human risk evaluation. However, any immune perturbation documented in rodents following xenobiotic exposure may conceivably be relevant to human risk assessment. The proven theoretical bases of humoral and cell-mediated immune responses and appreciation of the mechanisms of natural host resistance can be exploited in immunologically defined animals to yield important information regarding the site of immunotoxic damage following exposure to xenobiotics.
The recent evaluation ofa wide range ofchemicals has demonstrated that significant toxic effects manifested in the immune system of rodents include changes in lymphoid organ weights and histology, alterations in the humoral immune response (e.g., depressed ability to generate specific antibody Table VI . The next few years will be an exciting era in toxicology, as new methods are developed to examine
